header
February 19, 2020

In This Issue
IN THE SPOTLIGHT
No on 1: Time Is Short, We Need Your Help Now
The Maine Millennial: Donít Forget that Vaccines Save Lives
Maine CDC Infectious Disease Program Report
Maine's Weekly Influenza Report
Polio Eradication on UN Secretary Generalís Agenda During Pakistan Visit
Four Countries in the African Region License Vaccine in Milestone for Ebola Prevention
Physicians are Making Waves for the Purpose of Change
129th MAINE LEGISLATURE, SECOND REGULAR SESSION
Next MMA Legislative Call Will Be Tuesday, February 25th
State House Highlights of the Week
UPCOMING EVENTS
Upcoming Specialty Society Meetings
Maine Suicide Prevention Program Training for Clinicians
10th Annual Maine Patient Safety Academy - March 30, 2020
HEALTHCARE EMPLOYMENT OPPORTUNITIES
Medical Director, Primary Care Physician
Physician - Nasson Health Care
Nurse Practitioner - Nasson Health Care
Psychiatric Nurse Practitioner - Nasson Health Care
BC/BE Family Medicine or Internal Medicine Physician
Family Medicine Opportunity in Beautiful Western Maine
Orthopedic Surgeon Opportunity in Beautiful New England
VOLUNTEER OPPORTUNITIES
Opportunities at the VA for Volunteer Physicians
Volunteer Opportunity with Partners for World Health - Portland, ME

 
Search Back Issues



 

 

 

 

 


Follow Us:
Four Countries in the African Region License Vaccine in Milestone for Ebola Prevention

[From WHO 02/14/20]

Brazzaville/Geneva 14 February 2020 - The Democratic Republic of the Congo (DRC), Burundi, Ghana and Zambia have licensed an Ebola vaccine, just 90 days after World Health Organization (WHO) prequalification. Registration of the vaccine is expected in additional countries in the coming weeks.
 
The licensing of the vaccine means that the manufacturer can stockpile and widely distribute this vaccine to African countries at risk of Ebola virus disease outbreaks. Once licensed doses are available, use of the vaccine will not require clinical trial or other research protocols.
 
"The approval of the Ebola vaccine by these countries is another milestone in the fight against this unforgiving disease," said WHO Director-General Dr Tedros Adhanom Ghebreyesus. “Africa has rallied to cement hard-fought progress to keep its people safe from Ebola."
 
WHO accelerated the licensing and roll-out of the Ebola vaccine by certifying that it met the organization’s standards for quality, safety and efficacy in its fastest vaccine prequalification process ever, announced in November 2019.
 
The speed with which this has been achieved has been made possible by a different approach, where national licensing procedures were done in parallel based on one single scientific review process. Usually, these process are done one by one, which can take years. The process was led by WHO with the participation of the African Vaccine Regulatory Forum (an African network of national regulatory authorities and ethics committees), the European Medicines Agency, and Merck.
 
“The rapid approval of the Ebola vaccine by countries in the Africa Region helps ensure this critical prevention tool will be available when and where it is needed most,” said Dr Matshidiso Moeti, WHO Regional Director for Africa. “This kind of collaboration and innovation is a model for other health priorities.”
 
The injectable Ebola vaccine, Ervebo, is manufactured by Merck (known as MSD outside the US and Canada). Preliminary study results have shown a 97.5% vaccine efficacy. Data also suggests that vaccinating people who are already infected reduces their chances of dying.
 
In response to the ongoing Ebola outbreak in the DRC, over 290 000 people have been vaccinated under compassionate use protocols. Once licensed doses are available, use of the vaccine in DRC will no longer require these protocols.


https://www.who.int/news-room/detail/14-02-2020-four-countries-in-the-african-region-license-vaccine-in-milestone-for-ebola-prevention  

 

< Previous Article | Next Article >

[ return to top ]

To ensure delivery of Maine Medicine Weekly Update,
please add 'info@mainemed.com' to your email address book or Safe Sender List.
If you are still having problems receiving our communications,
see our white-listing page for more details: http://www.commpartners.com/website/white-listing.htm


Unsubscribe here

For more information or to contact us directly, please visit www.mainemed.com | ©